高级搜索
替吉奥胶囊联合奈达铂及紫杉醇治疗远处转移鼻咽癌疗效观察[J]. 肿瘤防治研究, 2011, 38(11): 1296-1298. DOI: 10.3971/j.issn.1000-8578.2011.11.020
引用本文: 替吉奥胶囊联合奈达铂及紫杉醇治疗远处转移鼻咽癌疗效观察[J]. 肿瘤防治研究, 2011, 38(11): 1296-1298. DOI: 10.3971/j.issn.1000-8578.2011.11.020
Clinical Efficacy of Compound Tegafur Capsule Plus Nedaplatin and Paclitaxel in Treatment of Patients with Distant Metastatic Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(11): 1296-1298. DOI: 10.3971/j.issn.1000-8578.2011.11.020
Citation: Clinical Efficacy of Compound Tegafur Capsule Plus Nedaplatin and Paclitaxel in Treatment of Patients with Distant Metastatic Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(11): 1296-1298. DOI: 10.3971/j.issn.1000-8578.2011.11.020

替吉奥胶囊联合奈达铂及紫杉醇治疗远处转移鼻咽癌疗效观察

Clinical Efficacy of Compound Tegafur Capsule Plus Nedaplatin and Paclitaxel in Treatment of Patients with Distant Metastatic Nasopharyngeal Carcinoma

  • 摘要: 目的评价替吉奥胶囊(compound tegafur capsule, S-1)联合奈达铂(NDP)及紫杉醇(PTX)方案治疗晚期鼻咽癌的临床疗效及不良反应。方法治疗晚期远处转移鼻咽癌患者21例,给予S-1 80 mg/m2,分2次,餐后口服,d1~14; NDP 80 mg/m2及PTX 135 mg/m2静脉滴注,第1天;每4周为1周期,所有患者均治疗2~4周期,按RECIST 1. 1标准评价客观疗效和不良反应。结果CR 3例(14.3%), PR 12例(57.1%), SD 5例(23.8%), PD 1例(4.8%),RR 71.4%。该方案最主要的不良反应为骨髓抑制,Ⅲ~Ⅳ度粒细胞减少占71.5%;Ⅱ~Ⅲ度血小板下降占52.3%,其余不良反应则可以耐受。结论替吉奥联合奈达铂、紫杉醇治疗晚期远处转移鼻咽癌的近期临床疗效较好,不良反应可以耐受,值得临床进一步研究验证。

     

    Abstract: ObjectiveTo evaluate the efficacy and toxicity Compound tegafur capsule(S-1) plus Nedaplatin and Paclitaxel (SNP) regimen in the treatment of distant metastatic nasopharyngeal carcinoma. MethodsTwenty-one patients with distant metastatic nasopharyngeal carcinoma were enrolled and treated with S-1 capsule 80 mg/m2 twice daily for 14 days plus nedaplatin 80 mg/m2 and paclitaxel 135 mg/m2 by intravenous drip on d1. Treatment was administered every 3 weeks for 2~4 cycles. ResultsThe total effective rate was 71.4%. Three cases were complete response(14.3% ), 12 cases were partial response(57.1% ), 5 cases was stable disease (23.8%), 1 case were progressing disease (4.8%). The main adverse effect was myelosuppression,such as grade Ⅲ~Ⅳ neutropenia in 71.5% of all cases and grade Ⅱ~Ⅲ thrombocytopenia in 52.3% of all cases. Other adverse effects could be tolerated. ConclutionSNP regimen was a safe and effective therapy for patients with metastatic nasopharyngeal carcinoma although the long-term effects still need further evaluation.

     

/

返回文章
返回